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SUMMARY: This study characterized the adverse events following immunization (AEFI) with the nov-
el influenza A (H1N1) 2009 vaccine in Korea. Data on immunization and AEFI were collected between
October 27, 2009 and March 15, 2010 through the national immunization registry and passive surveil-
lance systems. The frequency of AEFI and serious adverse events (SAEs) were calculated according to
age, sex, priority group, and vaccine type. In 13,758,527 vaccine recipients aged 6 months or older,
2,530 AEFI were reported (18.4 per 100,000 immunizations). The AEFI reporting rate was highest
among people aged 10–19 years (29.6 per 100,000 immunizations) and was higher in female recipients
than in male recipients (20.0 versus 16.7 per 100,000 immunizations). Most AEFIs were nonspecific sys-
tematic reactions that occurred within 24 h (77.4z) after vaccine administration. A total of 178 vaccine-
related SAEs were identified, and vaccine-related mortalities were not reported. This study showed that
the AEFI reporting rate after influenza A (H1N1) 2009 vaccinations was relatively high, especially in the
younger population. Mild systemic reactions accounted for the majority of reported AEFI, and fatal
SAEs were rare. This study also implied that passive surveillance might be an efficient safety monitoring
system that can detect relatively rare AEFI.
INTRODUCTION
A national influenza A (H1N1) immunization pro-
gram was conducted with great urgency in South Korea
in 2009 after the identification of the first patient in
Korea in May 2009. The safety of the mass vaccination
program against influenza A (H1N1) 2009 has been of
great public concern. A study has shown that the safety
of the H1N1 vaccine was similar to that of the seasonal
influenza vaccine and that their manufacturing proc-
esses were the same (1). Even though no serious adverse
events (SAEs) related to the seasonal influenza vaccine
have been reported in clinical trials, the government has
monitored the safety of the H1N1 vaccine in order to
rapidly detect any unexpected safety problems (2–4). In
addition, an adjuvant vaccine was used to enhance the
immunogenicity, and this caused concern about adverse
events in South Korea. Clinical trials of the new vac-
cines against the novel influenza A (H1N1) 2009 virus
did not have sufficient sample sizes or follow-up dura-
tions to identify rare adverse events (5,6). These trials
were not big enough to provide information on rare ad-
verse events, such as Guillain-Barr áe syndrome, which
was reported in individuals vaccinated against the swine
influenza that prevailed in 1976 (7).
The purpose of the present study was to investigate
the characteristics of adverse events following immuni-
zation (AEFI) against influenza A (H1N1) 2009 through
the national immunization registry system and the pas-
sive surveillance system.
MATERIALS AND METHODS
Background on the 2009 immunization campaign and
the AEFI surveillance systems in South Korea: All in-
fluenza A (H1N1) 2009 vaccines that were administered
during the nationwide immunization program in Korea
were domestically produced starting in June 2009. They
were monovalent, inactivated, and split-virus vaccines
for injection use. The Korean government established a
system to register all recipients of this new vaccine
through the national immunization registration system.
A nonadjuvant vaccine (hemagglutinin, 15 mg/0.5 mL)
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Table 1. AEFI against influenza A (H1N1) 2009 in Korea by demographic characteristics and vaccine type
Characteristic Total vaccine recipientsNo. (z)
Reported AEFI
No. (z)
AEFI reporting rate
per 100,000 immunization P
Age (y)
0.5–9 5,178,138 (37.6) 806 (31.9) 15.6
10–19 4,633,254 (33.7) 1,372 (54.2) 29.6
20–59 1,413,383 (10.3) 179 ( 7.1) 12.7 º0.0001
60–69 1,074,580 ( 7.8) 76 ( 3.0) 7.1
Æ70 1,459,172 (10.6) 97 ( 3.8) 6.6
Sex
Male 6,725,369 (48.9) 1,122 (44.3) 16.7
º0.0001
Female 7,033,158 (51.1) 1,408 (55.7) 20.0
Priority group
Healthcare workers 550,341 ( 4.0) 71 ( 2.8) 12.9
Students 6,507,784 (47.3) 1,764 (69.7) 27.1
Infants & preschool children 3,219,495 (23.4) 413 (16.3) 12.8
Pregnant women 82,551 ( 0.6) 17 ( 0.7) 20.6 º0.0001
Persons with chronic medical conditions 963,097 ( 7.0) 133 ( 5.3) 13.8
Elderly (Æ65 years old) 1,926,194 (14.0) 98 ( 3.9) 5.1
Others 509,065 ( 3.7) 34 ( 1.3) 6.7
Type of vaccine
Nonadjuvant 10,491,364 (76.3) 2,281 (90.1) 21.7
º0.0001
Adjuvant 3,267,163 (23.7) 249 ( 9.9) 7.6
Total 13,758,527 (100) 2,530 (100) 18.4
AEFI, adverse events following immunization.
was administered to healthcare workers, preschool chil-
dren aged 36 months to 6 years, elementary school
children, middle and high school adolescents, and
pregnant women. A half dose of the nonadjuvant vac-
cine (hemagglutinin, 7.5 mg/0.25 mL) was administered
twice at 4 week intervals to infants aged 6 to 35 months.
The MF59-adjuvanted vaccine (hemagglutinin, 3.75 mg/
0.25 mL) was administered to people with chronic medi-
cal conditions, the elderly (aged 65 years or older), mili-
tary personnel, and the rest of the general public. The
immunization was conducted in an orderly fashion to
each target group using a standard vaccine production
and distribution schedule.
The national AEFI management system is composed
of the AEFI passive surveillance system, the AEFI rapid
response system, and the AEFI investigation team. The
AEFI rapid response system reviews the AEFI, which
are reported through a web-based passive surveillance
system, and determines causality between a SAE and the
vaccine. If suspicious SAEs were reported, the AEFI
Response Committee reviewed the results of the AEFI
investigation and made a decision as to whether or not
that lot of vaccine would be banned from the immuniza-
tion program.
Study population: We obtained data from the Korean
national AEFI surveillance system between October 27,
2009 and March 15, 2010. According to the national
vaccination program, we could classify the study popu-
lation into 7 priority groups: healthcare workers, stu-
dents, infants and preschool children, pregnant women,
persons with chronic medical conditions, elderly (Æ65
years old), and others (8). A SAE was defined as any ad-
verse event that led to hospitalization. All reported
SAEs were reviewed by the AEFI investigation team and
then classified as a local or systemic reaction. A system-
ic reaction was further classified into 4 categories: neu-
rologic, allergic, gastrointestinal, and nonspecific. The
causal relationship with vaccine administration was as-
sessed according to the World Health Organization
causality assessment guidelines (9).
Statistical analysis: The frequencies of AEFI and
SAEs were calculated according to age, sex, and priority
group. The frequency and type of AEFI were further
studied separately for the nonadjuvant and adjuvant
vaccines. The reporting rate was estimated by dividing
the number of adverse events by the number of vaccina-
tion recipients during the study period. In order to de-
termine the denominators, we extracted data on the age
group, sex, priority group, and vaccine type of
recipients from the national immunization system dur-
ing the study period. The numerators were the number
of people who reported any type of AEFI because the
presence and types of AEFI were reported without hier-
archy and multiple types of AEFI could be reported for
one person. Chi-square test and logistic regression ana-
lyses were used to compare the reported AEFI rates be-
tween the different characteristics. The SAS software
package (version 9.2; SAS Institute, Cary, N.C., USA)
was used for statistical analyses.
RESULTS
During the 5-month study period, 13,758,527 people
received vaccinations, and 76.3z of them received the
nonadjuvant vaccine. A total of 2,530 reports of AEFI
were confirmed, thus making the overall AEFI report-
ing rate 18.4 per 100,000 immunizations (Table 1). The
AEFI reporting rate was highest in the 10–19-year age
group (29.6 per 100,000 immunizations). The AEFI
reporting rate was higher in women than in men. Stu-
dents had the highest AEFI reporting rate (27.1 per
100,000 immunizations) among the priority vaccination
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Table 2. Frequency and type of AEFI among recipients of nonadjuvant vaccine
Demographic
characteristic
Vaccine recipient
No.
People with
local reaction
No. (z)1)
People with systemic reaction, No. (z)1) People with
any AEFI
No. (z)
Odds
ratio PNeurologic Gastrointestinal Allergic Nonspecific
Age (y)
0.5–9 5,176,540 105 (13.0) 81 (10.0) 133 (16.5) 185 (22.9) 546 (67.8) 805 (35.3) 0.52 º0.0001
10–19 4,627,769 92 ( 6.7) 212 (15.5) 335 (24.4) 304 (22.2) 1,034 (75.4) 1,372 (60.1) 1.00 —
20–59 643,814 5 ( 5.0) 8 ( 8.0) 16 (16.0) 16 (16.0) 80 (80.0) 100 ( 4.4) 0.52 º0.0001
Æ60 43,241 1 (25.0) 0 ( 0) 1 (25.0) 1 (25.0) 1 (25.0) 4 ( 0.2) 0.31 0.0139
Sex
Male 5,305,540 101 ( 9.6) 130 (12.4) 213 (20.3) 213 (20.3) 765 (73.1) 1,047 (45.9) 1.00 —
Female 5,185,824 102 ( 8.3) 171 (13.9) 272 (22.0) 293 (23.7) 896 (72.6) 1,234 (54.1) 1.20 º0.0001
Total 10,491,364 203 (11.1) 301 (13.2) 485 (21.3) 506 (22.2) 1,661 (72.8) 2,281 (100)
1): Multiple responses were allowed, so the total row percentages will exceed 100.
Table 3. Frequency and type of AEFI among recipients of adjuvant vaccine
Demographic
characteristic
Vaccine recipient
No.
People with
local reaction
No. (z)1)
People with systemic reaction, No. (z)1) People with
any AEFI
No. (z)
Odds
ratio PNeurologic Gastrointestinal Allergic Nonspecific
Age (y)
20–59 769,569 12 (15.2) 7 ( 8.9) 9 (11.4) 23 (29.1) 48 (60.8) 79 (31.9) 1.54 0.0037
60–69 1,042,690 14 (19.2) 14 (19.2) 9 (12.3) 17 (23.3) 50 (68.5) 73 (29.4) 1.05 0.7262
Æ70 1,447,821 5 ( 5.2) 13 (13.5) 19 (19.8) 24 (25.0) 71 (74.0) 96 (38.7) 1.00 —
Sex
Male 1,415,331 10 (13.5) 7 ( 9.5) 10 (13.5) 23 (31.1) 46 (62.2) 74 (28.9) 1.00 —
Female 1,844,749 21 (12.1) 27 (15.5) 27 (15.5) 41 (23.6) 123 (70.7) 174 (71.1) 1.80 º0.0001
Total 3,260,080 31 (12.5) 34 (13.7) 37 (14.9) 64 (25.8) 169 (68.1) 248 (100)
1): Multiple responses were allowed, so the total row percentages will exceed 100.
This table excludes 1,598 subjects (male 827, female 771) aged 6 months–9 years and 5,485 subjects (male 3,671, female 1,814) aged 10–19
years, who were targeted for the nonadjuvant vaccine but received the adjuvant vaccine. Among them, one AEFI was reported.
groups (Table 1).
Among the 10,491,364 recipients of the nonadjuvant
vaccine, 2,281 people reported some type of AEFI (21.7
per 100,000 immunizations). In all age groups, the
majority of AEFI were nonspecific reactions, which
were followed by allergic reactions and gastrointestinal
symptoms. The AEFI reporting rate was the highest in
the 10–19-year age group. The reporting rate was higher
in women than in men, but the types of AEFI were simi-
lar between men and women (Table 2). There were
3,267,163 adjuvant vaccine recipients. However, 1,598
people from the group aged 6 months to 9 years and
5,485 people in the group aged 10 to 19 years were not
included. They were vaccinated with the adjuvant vac-
cine even though they were targeted for the nonadjuvant
vaccine. Among them, only one AEFI (nonspecific reac-
tion) was reported. Among the adjuvant vaccine
recipients, older age and female sex were associated with
a higher AEFI reporting rate (Table 3).
Among the 317 SAEs reported, 178 cases were deter-
mined to be related to the vaccine. However, there were
no deaths or miscarriages among the 178 vaccination-
related SAEs (Fig. 1). Of the reported 178 SAEs that
were proven to be related to the vaccine, 177 were sys-
temic reactions (Table 4) and 1 was a local reaction (cel-
lulitis). The neurologic reactions included 2 cases of
Guillain-Barr áe syndrome. The first case was that of a
16-year-old boy who had an onset time of 27 h after the
vaccination. The other case was that of a 35-year-old
man who had an onset time of 3 days after the vaccina-
tion. There was also a case of acute disseminated en-
cephalomyelitis (11-year-old girl with an onset time of 5
days after the vaccination), a case of acute transverse
myelitis, a case of Bicker-staff brainstem encephalitis, 3
cases of facial palsy, a case of myopathy, and 66 cases
of nonspecific peripheral neuropathy. Among the 178
vaccine-related SAEs reported, there were 18 cases of
allergic reactions, such as anaphylaxis (n＝ 5), anaphy-
lactoid reactions (n＝ 10), urticaria (n＝ 2), and aller-
gic purpura (n＝ 1). All 5 gastrointestinal reactions
consisted of nausea. In the 139 SAEs that were deter-
mined not to be related to the vaccination, 12 deaths
and 8 miscarriages were included. The causes of death
were intracerebral hemorrhage (3 male recipients and 3
female recipients; median onset time, 48 h), cardiac dis-
order (4 male recipients and 1 female recipient; median
onset time, 7 h), and enterorrhagia (1 male recipient;
onset time, 4 h). Autopsies were conducted for only 5
cases of death. Among the 8 miscarriages, 1 case (24-
year-old mother; onset time, 4 days; autopsy done) was
related to intrauterine growth retardation, and another
case (37-year-old mother; onset time, 3 days; autopsy
not done) was assumed to be related to chorioamnioni-
tis. The other 6 cases of miscarriage were of unknown
causes because no autopsy was done. The mean± SD
age and median onset time were 56± 21.7 years and 7 h
(interquartile range, 6–168) for 5 cardiac disorders; 21.3
± 29.8 years and 48 h for 6 brain disorders; and 1 year
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Fig. 1. Flow of identification and classification of serious adverse events (SAEs). 1) SAEs are defined as any adverse
events that lead to hospitalization, including life-threatening experience or residual disability. 2) Causality assessed
according to the WHO guidelines. 3) Types of SAE are described in Table 4. 4) Causes of death were 5 cardiac dis-
orders (4 males/1 female), 6 brain disorders (3 males/3 females), and 1 enterorrhagia (1 male). 5) Causes of mis-
carriages were 1 chorioamnionitis, 1 intrauterine growth retardation, and 6 unknown causes.
Table 4. Serious adverse event reported through the AEFI surveillance system, Korea 2009
Type of SAE1)
No. of SAEs Age (y)
Mean±SD
Onset time in hours
Median [interquartile range]Total Male/Female Nonadjuvant/Adjuvant vaccine
Local reaction (n＝1)
Cellulitis 1 1/0 1/0 8 13
Systemic reaction
Neurologic (n＝75)
Guillain-Barr áe syndrom 2 2/0 2/0 25.5±9.5 49.5 [27–72]
Acute disseminated encephalomyelitis 1 0/1 1/0 11 120
Acute transverse myelitis 1 1/0 1/0 7 144
Bicker-staff brainstem encephalitis 1 1/0 1/0 15 360
Facial palsy 3 1/2 3/0 15 48 [25–120]
Myopathy 1 1/0 1/0 16 7
Nonspecific peripheral neuropathy 66 30/36 66/0 12.9±2.7 7 [1–27]
Allergic (n＝18)
Anaphylaxis 5 2/3 5/0 14.4±1.7 3
Analphylactoid reaction 10 2/8 10/0 13.0±2.4 3.5 [1–24]
Urticaria 2 0/2 2/0 11.5±0.7 11 [6–16]
Allergic purpular 1 0/1 1/0 9 96
Gastrointestinal (n＝ 8)
Gastroenteropathy 8 3/5 8/0 12.3±4.0 2.5 [1–13.5]
Nonspecific (n＝76)
Myalgia 14 6/8 14/0 11.9±2.2 16 [4–48]
Headache 22 7/15 22/0 13.5±3.0 5 [3–28]
Lethargy 16 9/7 15/1 13.9±7.8 13 [1–27]
Fever 16 5/11 16/0 10.5±4.8 4 [1–26.5]
Dizziness 8 2/6 8/0 13.0±3.4 6.5 [2–23]
Total 178 73/105 177/1 14.4±11.1 6 [1–28]
1): SAEs are defined as any adverse events that lead to hospitalization including life-threatening experience or residual disability.
SAE, serious adverse event.
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and 4 h for enterorrhagia, respectively. For the miscar-
riages, the onset time was 72 h for chorioamnionitis, 96
h for intrauterine growth restriction, and a median of
108 h (interquartile range, 33–288 h) in 6 cases with
unknown causes.
DISCUSSION
This study showed an overall AEFI reporting rate of
18.4 per 100,000 immunizations. This was higher than
the rates reported in China (10.0 per 100,000 doses) or
in the USA (8.2 per 100,000 doses) but lower than the
rate in Denmark (179 per 100,000 immunizations)
(1,10). In addition, this rate was much higher than the
adverse event reporting rates after vaccinations against
the seasonal trivalent influenza of the years 2007–2008
(0.79 adverse events per 100,000 immunizations) and
2008–2009 (0.74 adverse events per 100,000 immuniza-
tions) in Korea. This study showed a relatively high rate
of AEFI reports, even though underreporting is a
known limitation of the passive surveillance system (5).
The most plausible explanations for the high reporting
rate are the high public awareness and the enhanced ef-
forts to increase the reporting of AEFI due to a number
of endeavors, such as the distribution of vaccine infor-
mation statements or media outreach. In addition, even
though the influenza (H1N1) 2009 vaccine was licensed
in a similar way as the seasonal influenza vaccine, the
public perceived it as a new vaccine. There is a known
tendency for an increase in the rates of reporting ad-
verse events after immunizations with newly licensed
vaccines (1,11).
The AEFI reporting rate among children and adoles-
cents (6 months to 9 years and 10 to 19 years of age, re-
spectively) was very high. The risk assessment reports
stated that the novel influenza A (H1N1) 2009 vaccina-
tion might be associated with a higher frequency of fatal
outcomes than the seasonal trivalent influenza in the
younger age group (12), which therefore increased the
rate of voluntary immunizations among this popula-
tion. As a result, infants and children made up the
majority of all recipients of the vaccine, and their vacci-
nation coverage rate was fairly high (8). Moreover, par-
ents and teachers were more likely to report potential
AEFI. Students were double-checked at home and at
school for any of the symptoms and signs. Some stu-
dents were hospitalized with only anxiety reactions,
hyperventilation syndrome, or mild nonspecific sym-
ptoms. These hospitalizations might have contributed to
the higher AEFI reporting rate among children and
adolescents.
It was recommended that individuals aged 65 years or
older were immunized with adjuvant vaccine in order to
enhance the immunologic reactions. Among the ad-
juvant vaccine recipients, older age groups reported rel-
atively fewer AEFI. This finding is consistent with a
previous study (13). In the literature, AEFI was more
frequently reported in adjuvant vaccine recipients than
in nonadjuvant vaccine recipients (10,14). However, we
could not properly compare the AEFI rates between the
vaccine types because the adjuvant and nonadjuvant
vaccines were targeted to different priority groups. The
Strategic Advisory Group of Experts advised that any
licensed pandemic vaccine can be used to protect preg-
nant women regardless of the type of vaccine without
specific contraindications (12,15). In the present study,
we identified 82,551 pregnant recipients and 17 AEFI (7
systemic reactions, 7 neurologic reactions, 2 gastrointes-
tinal reactions, and 1 local reaction) among them; there
were no SAEs associated with the vaccination.
Most of the reported AEFI were nonspecific reac-
tions, such as headache, fever, and myalgia, regardless
of the recipient's age and vaccine type. These results are
similar to a clinical study that was conducted in Italy
(16) but differ from the results of other studies
(1,3,16,17). The onset of AEFI was reported to usually
occur within 24 h after the vaccination in this study,
which is consistent with the findings of studies following
pandemic monovalent or seasonal trivalent vaccines
(18). SAEs, which are defined as hospitalizations after
vaccinations, accounted for 7z of all AEFI and
0.0001z of the total vaccine recipients. The majority of
SAEs were not fatal. However, people tended to be
admitted to the hospital even with mild nonspecific sym-
ptoms. Among the neurologic SAEs, nonspecific
peripheral neuropathy was the most common type, with
a rate of 0.5 per 100,000 immunizations. However, it
was difficult to diagnose certain neurologic diseases,
such as vaccine-related peripheral neuritis. These dis-
eases had different clinical aspects than the Guillain-
Barr áe syndrome and showed improvement within 2 or 3
days in most cases. Their prognoses were benign. Guil-
lain-Barr áe syndrome is a critical issue in aspects of vac-
cine vigilance that are relevant to the safety of vaccina-
tions, even though its causal relationship with the in-
fluenza vaccination is still controversial (19,20). The
reporting rate of the syndrome is known to be 0.8 to 1.9
per 1,000,000 vaccinations (7). In this study, 2 cases of
Guillain-Barr áe syndrome were identified by the passive
surveillance system with the nonadjuvant vaccine, and
they met the Brighton Collaboration Criteria Level 2 or
3 (21).
Our study did not directly observe the efficacy of the
influenza A (H1N1) 2009 vaccine in Korea. A previous
clinical trial reported excellent immunogenic results for
it. Although the immunogenicity was moderately differ-
ent between children, adolescents, and younger (18–64
years) and older (65 years or older) adults, seroprotec-
tion and seroconversion rates were significantly greater
than the criteria set by the E.U. Committee for Medici-
nal Products for Human Use and the US Food and
Drug Administration for all age groups (17,22).
Another case-control study reported that the influenza
A (H1N1) 2009 vaccine was substantially protective
against pandemic influenza in Korea during the
2009–2010 season. The overall vaccine efficacy was esti-
mated at 73.4z with a 95z confidence interval of
49.1–86.1z (23). Taken together, these previous studies
and our current findings support that the influenza A
(H1N1) 2009 monovalent vaccine was safe and efficient.
The goal of this study was to determine the AEFI and
safety of the novel influenza A (H1N1) 2009 vaccine by
analyzing data from the passive surveillance system and
the national immunization registry system of South
Korea. These systems include the entire Korean popula-
tion who were vaccinated. However, we could not estab-
lish a causal relationship due to the limitations of the
passive surveillance system. Another limitation is that
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we could not properly compare AEFI between the ad-
juvant and nonadjuvant vaccines because they were
recommended for different vaccination priority groups.
In addition, we were unable to compare the AEFI
reporting rate between influenza A (H1N1) 2009 and
previous seasonal influenza vaccinations because the na-
tional immunization registry system for the seasonal in-
fluenza vaccination was started only very recently.
This study found that the AEFI reporting rate after
influenza A (H1N1) 2009 vaccination was relatively
high, especially in the younger population. Mild system-
ic reactions accounted for the majority of reported
AEFI, and fatal SAEs were rare. In addition, this study
implied that a passive surveillance system may be an ef-
ficient and fast safety monitoring system for mass vacci-
nation programs because it can detect relatively rare
AEFI.
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